Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neuphoria Therapeutics (NEUP) Revenue (2024 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Revenue for 2 consecutive years, with -$13267.0 as the latest value for Q2 2025.

  • Quarterly Revenue changed N/A to -$13267.0 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $15.0 million through Dec 2025, up 2161.41% year-over-year, with the annual reading at $15.6 million for FY2025, N/A changed from the prior year.
  • Revenue for Q2 2025 was -$13267.0 at Neuphoria Therapeutics, down from $15.0 million in the prior quarter.
  • The five-year high for Revenue was $15.0 million in Q1 2025, with the low at -$13267.0 in Q2 2025.